(MedPage Today) — Etranacogene dezaparvovec (Hemgenix), the only commercially available gene therapy for hemophilia B, is temporarily unavailable, according to maker CSL Behring.
In a letter addressed to the hemophilia B community, the company…
Source link
Gene Therapy Supply Runs Out, Company Warns of Treatment Delays
Show Comments (0)
Hide Comments (0)
0
0
votes
Article Rating
Subscribe
Login
0 Comments
Oldest
Newest
Most Voted
Inline Feedbacks
View all comments
